Trial Profile
Acute candesartan cilexetil outcomes stroke trial (ACCOST)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms ACCOST
- 07 Oct 2009 Actual end date (Jun 2006) added as reported by ISRCTN: Current Controlled Trials.
- 07 Oct 2009 Additional lead trial centres and investigators identified as reported by ISRCTN: Current Controlled Trials.
- 07 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.